Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 5;132(1):78-85.
doi: 10.1097/CM9.0000000000000006.

Herbal medicine in the treatment of patients with type 2 diabetes mellitus

Affiliations
Review

Herbal medicine in the treatment of patients with type 2 diabetes mellitus

Guo-Ming Pang et al. Chin Med J (Engl). .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
The anti-inflammatory effect of herbal medicine in type 2 diabetes mellitus. TNF-α: tumor necrosis factor-α; TLR4-MyD88: toll-like receptor 4-myeloid differential protein-88; IL-1β: interleukin-1β; NLRP3: NACHT, LRR, and PYD domain-containing protein 3; WMW: Wu-Mei-Wan; NF-κB: nuclear transcription factor kappa B; IκBα: inhibitor of NF-κB; COX2: cyclo-oxgenase 2; IL-8: interleukin-8; IL-6: interleukin-6.
Figure 2
Figure 2
The anti-oxidation effect of herbal medicine in type 2 diabetes mellitus. SOD: superoxide dismutase; CAT: catalase; GSH-px: glutathione peroxidase; iNOS: inducible nitric oxide synthase; MDA: malondialdehyde.
Figure 3
Figure 3
The regulating blood lipids effect of herbal medicine in type 2 diabetes mellitus. TG: triglyceride; LDL: low-density lipoprotein; TC: total cholesterol; HDL: high-density lipoprotein; FFA: free fatty acids; ACC: acetyl-coenzyme A carboxylase; ACAT2: acetyl-coenzyme A acetyltransferase 2.
Figure 4
Figure 4
The anti-glucose effect of herbal medicine in type 2 diabetes mellitus. GLP-1: glucagon-like peptide-1 (7–36) amide; DPP-4: dipeptidyl-peptidase 4.
Figure 5
Figure 5
The effect of herbal medicine in type 2 diabetes mellitus.

References

    1. DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers 2015; 1:15019.doi:10.1038/nrdp.2015.19. - PubMed
    1. Kowluru A, Kowluru RA. RACking up ceramide-induced islet beta-cell dysfunction. Biochem Pharmacol 2018; 154:161–169. doi:10.1016/j.bcp.2018.04.026. - PMC - PubMed
    1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414:782–787. doi:10.1038/414782a. - PubMed
    1. Maletkovic J, Drexler A. Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Endocrinol Metab Clin North Am 2013; 42:677–695. doi:10.1016/j.ecl.2013.07.001. - PubMed
    1. Hickner J. Diabetes care: whose goals are they? J Fam Pract 2014; 63:420. - PubMed

MeSH terms